<DOC>
	<DOCNO>NCT01857245</DOCNO>
	<brief_summary>Injection drug user ( IDUs ) constitute 60 % approximately 5 million people U.S. infect hepatitis C virus ( HCV ) . HCV treatment lead sustained viral response ( SVR ) associate increased survival . However , IDUs poor access HCV care success HCV treatment limit . With direct-acting antiviral agent , HCV treatment deliver within large clinical trial lead SVR cure 70 % genotype-1 infected patient , compare 45 % previous therapy . However , SVR rate low 14 % real-world setting . The majority patient fail achieve SVR develop drug resistance , optimal adherence level minimize resistance unknown . If HCV treatment continue deliver within current model care , IDUs fail treatment develop resistance , may transmit resistant virus others . We previously develop multidisciplinary model HCV care integrate on-site primary care , substance abuse treatment , psychiatric care , HCV-related care within opiate agonist treatment clinic . To maximize treatment outcome , pilot two model intensive HCV-related care : directly observe therapy ( DOT ) , concurrent group therapy ( CGT ) . In DOT model , pegylated interferon administer weekly , applicable , one daily dose oral medication administer methadone window . In CGT model , patient initiate HCV treatment within weekly treatment group provide powerful social support mitigate fear side effect , promote efficient education , deliver weekly injection , applicable . It unknown whether either model well cost-effective standard on-site care . PREVAIL 1 : In propose study , 150 IDUs chronic HCV ( genotype 1 ) recruit methadone clinic randomize one three model care : DOT ; concurrent group treatment ; standard on-site care . Our specific aim : 1 ) To determine whether either two intensive on-site HCV treatment model ( DOT concurrent group treatment ) efficacious standard on-site treatment enhance adherence SVR , decrease drug resistance ; ( 2 ) To determine incidence factor associate development drug resistance IDUs ; ( 3 ) To perform cost cost-effectiveness analysis model ; ( 4 ) To examine impact HIV coinfection adherence virologic outcome among HCV-infected IDUs . PREVAIL 2 : In propose study , 60 IDUs chronic HCV ( genotypes 1 2 , 3 4 ) recruit opiate agonist treatment program start HCV treatment . Subjects offer choice model care ( either standard on-site , DOT , concurrent group treatment ) . Our specific aim : ( 1 ) determine rate adherence SVR cohort opiate agonist treatment patient initiate treatment sofosbuvir-based regimen ( 2 ) determine adherence rate time drug user ( genotype 3 genotype 1 / IFN-ineligible ) initiate 24 week IFN-free regimen . PREVAIL 3 : In propose study , 60 IDUs chronic HCV ( genotype 1 4 ) recruit opiate agonist treatment program start HCV treatment . Subjects offer choice model care ( either standard on-site , DOT , concurrent group treatment ) . Our specific aim : ( 1 ) determine rate adherence SVR cohort opiate agonist treatment patient initiate treatment oral DAA combination sofosbuvir simeprevir fix dose sofosbuvir ledipasvir ( 2 ) determine adherence rate time drug user .</brief_summary>
	<brief_title>Intensive Models HCV Care Injection Drug Users</brief_title>
	<detailed_description>PREVAIL 1 : In propose study , 150 IDUs chronic HCV ( genotype 1 ) recruit methadone clinic randomize one three model care : DOT ; concurrent group treatment ; standard on-site care . Our specific aim : 1 ) To determine whether either two intensive on-site HCV treatment model ( DOT concurrent group treatment ) efficacious standard on-site treatment enhance adherence SVR , decrease drug resistance ; ( 2 ) To determine incidence factor associate development drug resistance IDUs ; ( 3 ) To perform cost cost-effectiveness analysis model ; ( 4 ) To examine impact HIV coinfection adherence virologic outcome among HCV-infected IDUs . PREVAIL 2 : In propose study , 60 IDUs chronic HCV ( genotypes 1 2 , 3 4 ) recruit opiate agonist treatment program start HCV treatment . Subjects offer choice model care ( either standard on-site , DOT , concurrent group treatment ) . Our specific aim : ( 1 ) determine rate adherence SVR cohort opiate agonist treatment patient initiate treatment sofosbuvir-based regimen ( 2 ) determine adherence rate time drug user ( genotype 3 genotype 1 / IFN-ineligible ) initiate 24 week IFN-free regimen . PREVAIL 3 : In propose study , 60 IDUs chronic HCV ( genotype 1 4 ) recruit opiate agonist treatment program start HCV treatment . Subjects offer choice model care ( either standard on-site , DOT , concurrent group treatment ) . Our specific aim : ( 1 ) determine rate adherence SVR cohort opiate agonist treatment patient initiate treatment oral DAA combination sofosbuvir simeprevir fix dose sofosbuvir ledipasvir ( 2 ) determine adherence rate time drug user .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Methadone</mesh_term>
	<criteria>Eligibility Ages Eligible Study : 18 Years old Genders Eligible Study : Both PREVAIL 1 : HCVinfected , Genotype1 Treatment naïve treatment experience patient Willing receive HCV treatment onsite Initiating treatment directacting antiviral agent ( DAA ) without ribavirin +/ pegylated interferon alfa2a Receiving methadone buprenorphine clinic least one time per week Age 18 old Able provide inform consent Psychiatrically stable English Spanish speak Currently enrol methadone buprenorphine treatment program designate clinic Bronx ( Melrose , Port Morris , Waters Place ) Known hypersensitivity ( allergy ) interferon , ribavirin DAA Psychiatrically unstable Pregnant breastfeeding PREVAIL 2 : HCVinfected , Genotype1 , , 2 , 3 , 4 Willing receive HCV treatment onsite opiate agonist treatment program . Initiating treatment sofosbuvir ribavirin +/ pegylated interferon alfa2a Age 18 old Able provide inform consent English Spanish speak Currently patient one designate clinic Bronx ( Melrose , Port Morris , Waters Place ) Known hypersensitivity ( allergy ) interferon , ribavirin sofosbuvir Pregnant breastfeeding PREVAIL 3 : HCVinfected , Genotype1 4 Willing receive HCV treatment onsite opiate agonist treatment program . Initiating treatment oral DAA combination sofosbuvir simeprevir fix dose sofosbuvir ledipasvir . Age 18 old Able provide inform consent English Spanish speak Currently patient one designate clinic Bronx ( Melrose , Port Morris , Waters Place ) Known hypersensitivity ( allergy ) sofosbuvir , simprevir ledipasvir . Pregnant breastfeed PREVAIL 4 HCVinfected , Genotype1 Treatment naïve treatment experience patient Willing receive HCV treatment onsite Initiating treatment directacting antiviral agent ( DAA ) without ribavirin +/ pegylated interferon alfa2a Age 18 old Able provide inform consent Psychiatrically stable English Spanish speak Known hypersensitivity ( allergy ) interferon , ribavirin DAA Psychiatrically unstable Pregnant breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>addiction</keyword>
	<keyword>Adherence ( attribute )</keyword>
	<keyword>Adverse effect</keyword>
	<keyword>Agonist</keyword>
	<keyword>Antiviral Agents</keyword>
	<keyword>arm</keyword>
	<keyword>base</keyword>
	<keyword>care delivery</keyword>
	<keyword>Caring</keyword>
	<keyword>Chronic Hepatitis C</keyword>
	<keyword>Clinic</keyword>
	<keyword>Clinical Trials</keyword>
	<keyword>Complex</keyword>
	<keyword>Computer Simulation</keyword>
	<keyword>cost</keyword>
	<keyword>cost effective</keyword>
	<keyword>cost effectiveness</keyword>
	<keyword>Data</keyword>
	<keyword>Development</keyword>
	<keyword>Directly Observed Therapy</keyword>
	<keyword>Disease</keyword>
	<keyword>Dose</keyword>
	<keyword>Drug resistance</keyword>
	<keyword>drug resistant virus</keyword>
	<keyword>Educational aspect</keyword>
	<keyword>Epidemic</keyword>
	<keyword>experience</keyword>
	<keyword>Frequencies ( time pattern )</keyword>
	<keyword>Fright</keyword>
	<keyword>Genotype</keyword>
	<keyword>Group Therapy</keyword>
	<keyword>Health Care Costs</keyword>
	<keyword>Health Personnel</keyword>
	<keyword>Healthcare Systems</keyword>
	<keyword>Hepatitis C</keyword>
	<keyword>Hepatitis C Prevalence</keyword>
	<keyword>Hepatitis C Transmission</keyword>
	<keyword>Hepatitis C virus</keyword>
	<keyword>HIV</keyword>
	<keyword>Homelessness</keyword>
	<keyword>improve</keyword>
	<keyword>Incidence</keyword>
	<keyword>Infection</keyword>
	<keyword>Injecting drug user</keyword>
	<keyword>Injection therapeutic agent</keyword>
	<keyword>Intensive Care</keyword>
	<keyword>Interferons</keyword>
	<keyword>Intervention</keyword>
	<keyword>Knowledge</keyword>
	<keyword>Life</keyword>
	<keyword>Liver disease</keyword>
	<keyword>Liver Failure</keyword>
	<keyword>liver transplantation</keyword>
	<keyword>Living Costs</keyword>
	<keyword>Mental disorder</keyword>
	<keyword>Methadone</keyword>
	<keyword>methadone clinic/center</keyword>
	<keyword>Modeling</keyword>
	<keyword>Mortality Vital Statistics</keyword>
	<keyword>Motivation</keyword>
	<keyword>multidisciplinary</keyword>
	<keyword>Opiates</keyword>
	<keyword>Oral</keyword>
	<keyword>Outcome</keyword>
	<keyword>Patients</keyword>
	<keyword>Persons</keyword>
	<keyword>Pharmaceutical Preparations</keyword>
	<keyword>Physicians</keyword>
	<keyword>pill ( pharmacologic )</keyword>
	<keyword>Play</keyword>
	<keyword>Poverty</keyword>
	<keyword>Primary Health Care</keyword>
	<keyword>program</keyword>
	<keyword>Psychiatric therapeutic procedure</keyword>
	<keyword>psychosocial</keyword>
	<keyword>Publishing</keyword>
	<keyword>Quality-Adjusted Life Years</keyword>
	<keyword>Randomized</keyword>
	<keyword>Randomized Controlled Trials</keyword>
	<keyword>randomize trial</keyword>
	<keyword>Recruitment Activity</keyword>
	<keyword>Regimen</keyword>
	<keyword>Resistance</keyword>
	<keyword>Resistance development</keyword>
	<keyword>response</keyword>
	<keyword>Risk</keyword>
	<keyword>risk perception</keyword>
	<keyword>Role</keyword>
	<keyword>Site</keyword>
	<keyword>skill</keyword>
	<keyword>Social support</keyword>
	<keyword>standard care</keyword>
	<keyword>substance abuse treatment</keyword>
	<keyword>success</keyword>
	<keyword>Time</keyword>
	<keyword>Treatment outcome</keyword>
	<keyword>Treatment Protocols</keyword>
	<keyword>treatment site</keyword>
	<keyword>Trust</keyword>
	<keyword>United States</keyword>
	<keyword>Viral</keyword>
	<keyword>Virus</keyword>
</DOC>